Courier Capital LLC Sells 384 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Courier Capital LLC decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 5,670 shares of the medical equipment provider’s stock after selling 384 shares during the period. Courier Capital LLC’s holdings in Zimmer Biomet were worth $599,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Dunhill Financial LLC boosted its holdings in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet during the 3rd quarter worth about $28,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet during the 3rd quarter worth about $31,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $35,000. Finally, Quarry LP acquired a new stake in shares of Zimmer Biomet in the second quarter valued at about $53,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $105.36 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The firm has a market cap of $20.97 billion, a price-to-earnings ratio of 20.03, a P/E/G ratio of 1.96 and a beta of 1.02. The stock’s fifty day moving average price is $107.97 and its two-hundred day moving average price is $108.00. Zimmer Biomet Holdings, Inc. has a one year low of $100.67 and a one year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the company posted $1.65 earnings per share. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Wells Fargo & Company raised their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Oppenheimer decreased their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research note on Tuesday, October 15th. Evercore ISI dropped their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Royal Bank of Canada lifted their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, November 4th. Finally, Truist Financial upped their target price on shares of Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $123.33.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.